ADHDVECTORNCT07039903
A Novel Psychological Intervention for Adults With Bipolar Disorder and Attention Deficit Hyperactivity Disorder Comorbidity (VECTOR)
A study testing Cognitive behavioral therapy (CBT) + Functional Remediation (FR) in people with ADHD and BD, run by Hospital Universitari Vall d'Hebron Research Institute at 1 site in Spain.
Trial summary
Cognitive dysfunctions are present in Bipolar Disorder (BD) and Attention Deficit Hyperactivity Disorder (ADHD) and may negatively impact psychosocial functioning. Further, comorbid BD and ADHD (BD-ADHD) is prevalent, associated with an earlier BD onset and a less favorable prognosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- Cognitive behavioral therapy (CBT) + Functional Remediation (FR)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 68 participants
- Where
- 1 siteSpain
- Study dates
- 1 Sep 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Fulfill DSM-5 criteria for BDI or BDII and ADHD using the Structured Clinical Interview for DSM-5 and the Conners' Adult ADHD Diagnostic Interview (CAARS)
- Aged ≥18
- Stable pharmacological treatment for at least the past three months.
- Being in full or partial remission Young Mania Rating Scale (YMRS) ≤ 10, Hamilton Depression Rating Scale (HDRS) ≤ 14) at the time of the inclusion and assessment
- ADHD rating scale≥24
Who cannot join
- Any comorbid psychiatric condition
- Diagnosis of substance abuse disorder in the past 12 months
- Intellectual disability (intelligence quotient < 70)
- Having any Central Nervous System illness, independent of primary psychiatric diagnosis, hampering neuropsychological performance
- Participation in a structured psychological intervention during the study period.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
Hospital Clínic de Barcelona and Vall d'Hebron University Hospital
Barcelona, Barcelona, 08035
Silvia Amoretti, PhD, +34935578820, Silvia.amoretti@vhir.org
Carla Torrent, PhD, ctorrent@recerca.clinic.cat
About this study
Official title: Bridging the Gap in the Study of Bipolar Disorder and Attention Deficit Hyperactivity Disorder: Impact of cognitiVE Reserve and funCtioning in a Newly Designed Treatment intervenTion for comORbidity (VECTOR)
Cognitive dysfunctions are present in Bipolar Disorder (BD) and Attention Deficit Hyperactivity Disorder (ADHD) and may negatively impact psychosocial functioning. Further, comorbid BD and ADHD (BD-ADHD) is prevalent, associated with an earlier BD onset and a less favorable prognosis. Nevertheless, there is a paucity of research dedicated to the characterization and treatment of comorbid BD-ADHD.
This study aims to develop and evaluate the effectiveness of a novel psychological group intervention (VECTOR) for adults with BD-ADHD. VECTOR integrates elements from Cognitive Behavioral Therapy (CBT) for ADHD and Functional Remediation (FR) for BD.
Read more
Eighty patients will be randomized (1:1) to receive either the VECTOR program (12 weekly group sessions) or treatment as usual (TAU).
It is expected that the VECTOR program will result in greater improvements in functioning and symptom reduction compared to TAU.
- Being tested
- Cognitive behavioral therapy (CBT) + Functional Remediation (FR)
- Keywords
- clinical trial, Cognitive Behavioral Therapy, Psychological treatment, Bipolar Disorder, Bipolar and Related Disorders, BD, Attention-Deficit Hyperactivity Disorder, ADHD, Functional remediation
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity, Bipolar Disorder, Bipolar and Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive behavioral therapy (CBT) + Functional Remediation (FR)Behavioural
VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013).
| Study group | Role | What they receive |
|---|---|---|
| VECTOR program | Experimental | The VECTOR enhancement protocol consists of 12 weekly sessions (90 minutes each of them) in a group format (8-10 individuals) with audiovisual support. Receives: Behavioral: Cognitive behavioral therapy (CBT) + Functional Remediation (FR) |
| Treatment as usual (TAU) | No intervention | All participants will receive standard care in accordance with the current practice at the participating centre, respecting international recommendations for the management of their illness. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functioning Assessment Short Test (FAST)
24-item scale assessing disability in six functional domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Assessed by a blind expert rater.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Clinical Global Impression - Severity (CGI-S)
Severity scale measuring global symptom severity. Assessed by a blind expert rater.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Secondary outcomes (11)
Change in the ADHD-Rating Scale (ADHD-RS)
The ADHD-RS is an 18-items scale self-report version for assessing symptoms for ADHD DSM-IV. It consists of a subscale of inattention (IN, 9-items), another of hyperactivity/impulsivity (H / I, 9-items) and the total (TOT, 18-items). The interviewees are asked about the frequency of the symptoms over the past 6 months.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in the severity of ADHD symptoms
Assessed by Connors' Adult ADHD Rating Scales Self-report form (CAARS-S:L), a self-report questionnaire evaluating the severity of ADHD symptoms across multiple domains, including inattention and hyperactivity/impulsivity.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in the severity of ADHD symptoms
Assessed by Connors' Adult ADHD Rating Scales Observer form (CAARS-O-L), an observer-rated questionnaire assessing ADHD symptom severity based on third-party observation, covering the same symptom domains as the self-report version.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in the Hamilton Depression
Each item is rated on either a 3-point or 5-point Likert-type scale, depending on the symptom being assessed, with higher scores indicating greater severity of depression. The total score for the HDRS-17 ranges from 0 to 52. Common domains evaluated include mood, guilt, suicide ideation, insomnia, anxiety, psychomotor changes, and somatic symptoms.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in the Young Mania Rating Scale (YMRS)
11-item clinician-rated scale used to assess manic symptoms such as elevated mood, increased motor activity, sleep disturbance, irritability, and thought disorder. Higher scores reflect more severe manic symptoms. Assessed by a blind expert rater.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in attention - Trail Making Test Part A (TMT-A)
TMT-A assesses processing speed and visual attention. Participants are asked to connect numbered circles in sequence as quickly as possible. Completion time is the outcome measure; shorter times indicate better performance.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in cognitive flexibility - Trail Making Test Part B (TMT-B)
TMT-B assesses cognitive flexibility, task-switching, and executive control. Participants alternate between numbers and letters in sequence (e.g., 1-A-2-B...). Completion time is recorded, with shorter times indicating better performance.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in sustained attention - Conners' Continuous Performance Test (CPT)
The CPT is a computerized test that measures sustained attention and impulsivity by recording responses to a series of visual stimuli. Key outcomes include omission errors, commission errors, and reaction time variability.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in executive function - Wisconsin Card Sorting Test (WCST)
The WCST measures cognitive flexibility and executive functioning. Participants must match cards according to varying rules. Key outcomes include number of categories completed and perseverative errors.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in inhibitory control - Stroop Test
The Stroop Color-Word Test evaluates selective attention and inhibitory control by measuring the ability to name the color of the ink rather than reading the printed word. Interference score is commonly used.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Change in verbal fluency - Phonemic and Semantic Fluency (PMR)
The Verbal Fluency Test assesses executive control and language by requiring the participant to generate as many words as possible starting with a letter (phonemic) or within a category (semantic) in a limited time.
Measured: Baseline, post-treatment (12 weeks) and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2025
- Study start1 Sep 2025 (estimated)
- Primary completion31 Jul 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for ADHDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 68 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Clinic of Barcelona
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07039903
- Sponsor's protocol ID
- PR(AG)041-2025
- Other IDs
- PI24/00671 and PI24/00407
- Acronym
- VECTOR
- Status last verified
- Jun 2025
- First submitted
- 18 Jun 2025
- Last updated
- 26 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We do not plan to share individual participant data (IPD) due to ethical and legal constraints related to data privacy and participant confidentiality, in accordance with applicable regulations and institutional policies.
Publications
Torrent C, Bonnin Cdel M, Martinez-Aran A, Valle J, Amann BL, Gonzalez-Pinto A, Crespo JM, Ibanez A, Garcia-Portilla MP, Tabares-Seisdedos R, Arango C, Colom F, Sole B, Pacchiarotti I, Rosa AR, Ayuso-Mateos JL, Anaya C, Fernandez P, Landin-Romero R, Alonso-Lana S, Ortiz-Gil J, Segura B, Barbeito S, Vega P, Fernandez M, Ugarte A, Subira M, Cerrillo E, Custal N, Menchon JM, Saiz-Ruiz J, Rodao JM, Isella S, Alegria A, Al-Halabi S, Bobes J, Galvan G, Saiz PA, Balanza-Martinez V, Selva G, Fuentes-Dura I, Correa P, Mayoral M, Chiclana G, Merchan-Naranjo J, Rapado-Castro M, Salamero M, Vieta E. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013 Aug;170(8):852-9. doi: 10.1176/appi.ajp.2012.12070971.
PubMed 23511717Corrales M, Garcia-Gonzalez S, Richarte V, Fadeuilhe C, Daigre C, Garcia-Gea E, Ramos-Quiroga JA. Long-term efficacy of a new 6-session cognitive behavioral therapy for adults with attention-deficit/hyperactivity disorder: A randomized, controlled clinical trial. Psychiatry Res. 2024 Jan;331:115642. doi: 10.1016/j.psychres.2023.115642. Epub 2023 Nov 27.
PubMed 38103281Amoretti S, De Prisco M, Clougher D, Garriga M, Corrales M, Fadeuilhe C, Forte MF, Martinez-Aran A, Oliva V, Parramon-Puig G, Richarte V, Amann BL, Oliva F, Ruiz A, Sole B, Valenti M, Crespin JJ, Arteaga-Henriquez G, Vieta E, Ramos-Quiroga JA, Torrent C. Neurocognitive and psychosocial functioning profiles in bipolar disorder and comorbid attention deficit hyperactivity disorder: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2025 Apr;171:106081. doi: 10.1016/j.neubiorev.2025.106081. Epub 2025 Feb 26.
PubMed 40015388
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bridging the Gap in the Study of Bipolar Disorder and Attention Deficit Hyperactivity Disorder: Impact of cognitiVE Reserve and funCtioning in a Newly Designed Treatment intervenTion for comORbidity (VECTOR)
- ClinicalTrials.gov ID
- NCT07039903
- Acronym / sponsor ID
- VECTOR / PR(AG)041-2025
- Keywords
- clinical trial, Cognitive Behavioral Therapy, Psychological treatment, Bipolar Disorder, Bipolar and Related Disorders, BD, Attention-Deficit Hyperactivity Disorder, ADHD
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 68 participants (estimated)
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research InstituteUniversity, hospital or other
- Collaborators
- Hospital Clinic of Barcelona
- Study start
- 1 Sep 2025 (estimated)
- Primary completion
- 31 Jul 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 26 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cognitive dysfunctions are present in Bipolar Disorder (BD) and Attention Deficit Hyperactivity Disorder (ADHD) and may negatively impact psychosocial functioning. Further, comorbid BD and ADHD (BD-ADHD) is prevalent, associated with an earlier BD onset and a less favorable prognosis. Nevertheless, there is a paucity of research dedicated to the characterization and treatment of comorbid BD-ADHD.
This study aims to develop and evaluate the effectiveness of a novel psychological group intervention (VECTOR) for adults with BD-ADHD. VECTOR integrates elements from Cognitive Behavioral Therapy (CBT) for ADHD and Functional Remediation (FR) for BD.
Eighty patients will be randomized (1:1) to receive either the VECTOR program (12 weekly group sessions) or treatment as usual (TAU).
It is expected that the VECTOR program will result in greater improvements in functioning and symptom reduction compared to TAU.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| VECTOR program | Experimental | Behavioral: Cognitive behavioral therapy (CBT) + Functional Remediation (FR)The VECTOR enhancement protocol consists of 12 weekly sessions (90 minutes each of them) in a group format (8-10 individuals) with audiovisual support. |
| Treatment as usual (TAU) | No intervention | –All participants will receive standard care in accordance with the current practice at the participating centre, respecting international recommendations for the management of their illness. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Fulfill DSM-5 criteria for BDI or BDII and ADHD using the Structured Clinical Interview for DSM-5 and the Conners' Adult ADHD Diagnostic Interview (CAARS)
- Aged ≥18
- Stable pharmacological treatment for at least the past three months.
- Being in full or partial remission Young Mania Rating Scale (YMRS) ≤ 10, Hamilton Depression Rating Scale (HDRS) ≤ 14) at the time of the inclusion and assessment
- ADHD rating scale≥24
Key exclusion criteria (5 listed)
- Any comorbid psychiatric condition
- Diagnosis of substance abuse disorder in the past 12 months
- Intellectual disability (intelligence quotient < 70)
- Having any Central Nervous System illness, independent of primary psychiatric diagnosis, hampering neuropsychological performance
- Participation in a structured psychological intervention during the study period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive behavioral therapy (CBT) + Functional Remediation (FR)VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013). | Behavioural | VECTOR program |
Primary outcome
Functioning Assessment Short Test (FAST)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
24-item scale assessing disability in six functional domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Assessed by a blind expert rater.
Clinical Global Impression - Severity (CGI-S)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Severity scale measuring global symptom severity. Assessed by a blind expert rater.
11 secondary outcomes
Change in the ADHD-Rating Scale (ADHD-RS)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in the severity of ADHD symptoms
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in the severity of ADHD symptoms
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in the Hamilton Depression
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in the Young Mania Rating Scale (YMRS)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in attention - Trail Making Test Part A (TMT-A)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in cognitive flexibility - Trail Making Test Part B (TMT-B)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in sustained attention - Conners' Continuous Performance Test (CPT)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in executive function - Wisconsin Card Sorting Test (WCST)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in inhibitory control - Stroop Test
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Change in verbal fluency - Phonemic and Semantic Fluency (PMR)
Time frame: Baseline, post-treatment (12 weeks) and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2025.
- Results publication: PubMed 23511717Torrent C, Bonnin Cdel M, Martinez-Aran A, Valle J, Amann BL, Gonzalez-Pinto A, Crespo JM, Ibanez A, Garcia-Portilla MP, Tabares-Seisdedos R, Arango C, Colom F, Sole B, Pacchiarotti I, Rosa AR, Ayuso-Mateos JL, Anaya C, Fernandez P, Landin-Romero R, Alonso-Lana S, Ortiz-Gil J, Segura B, Barbeito S, Vega P, Fernandez M, Ugarte A, Subira M, Cerrillo E, Custal N, Menchon JM, Saiz-Ruiz J, Rodao JM, Isella S, Alegria A, Al-Halabi S, Bobes J, Galvan G, Saiz PA, Balanza-Martinez V, Selva G, Fuentes-Dura I, Correa P, Mayoral M, Chiclana G, Merchan-Naranjo J, Rapado-Castro M, Salamero M, Vieta E. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013 Aug;170(8):852-9. doi: 10.1176/appi.ajp.2012.12070971.
- Results publication: PubMed 38103281Corrales M, Garcia-Gonzalez S, Richarte V, Fadeuilhe C, Daigre C, Garcia-Gea E, Ramos-Quiroga JA. Long-term efficacy of a new 6-session cognitive behavioral therapy for adults with attention-deficit/hyperactivity disorder: A randomized, controlled clinical trial. Psychiatry Res. 2024 Jan;331:115642. doi: 10.1016/j.psychres.2023.115642. Epub 2023 Nov 27.
- Results publication: PubMed 40015388Amoretti S, De Prisco M, Clougher D, Garriga M, Corrales M, Fadeuilhe C, Forte MF, Martinez-Aran A, Oliva V, Parramon-Puig G, Richarte V, Amann BL, Oliva F, Ruiz A, Sole B, Valenti M, Crespin JJ, Arteaga-Henriquez G, Vieta E, Ramos-Quiroga JA, Torrent C. Neurocognitive and psychosocial functioning profiles in bipolar disorder and comorbid attention deficit hyperactivity disorder: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2025 Apr;171:106081. doi: 10.1016/j.neubiorev.2025.106081. Epub 2025 Feb 26.
- Individual participant dataSharing planned: No. We do not plan to share individual participant data (IPD) due to ethical and legal constraints related to data privacy and participant confidentiality, in accordance with applicable regulations and institutional policies.
Related trials for ADHD
Not yet recruitingObservational study
Phase 1: Thrive Together: A Feasibility and Acceptability Evaluation of Peer Mentoring for High Schoolers With ADHD and Their Caregivers
Attention-Deficit/Hyperactivity Disorder (ADHD)
RecruitingPhase 3
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 2/3
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 4
AWARE: Management of ADHD in Autism Spectrum Disorder
ADHD, Autism Spectrum Disorder
Active, not recruiting
Pai.ACT: AI-Driven ACT Chatbot for Mental Health Triage and Service Evaluation
Autism Spectrum Disorder, Attention Deficit Disorder With Hyperactivity (ADHD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hospital Clínic de Barcelona and Vall d'Hebron University Hospital
Barcelona, Spain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive behavioral therapy (CBT) + Functional Remediation (FR) in people with ADHD and BD, run by Hospital Universitari Vall d'Hebron Research Institute at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functioning Assessment Short Test (FAST) (time frame: Baseline, post-treatment (12 weeks) and 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07039903, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2025; AzTrials last refreshed its copy on 26 Oct 2026.